Europe Next Generation Sequencing Market Size and Share Analysis - Growth Trends and Forecast Report 2024-2032

Europe Next Generation Sequencing Market Trends & Summary

Europe Next-Generation Sequencing market is estimated to reach US$12.95 billion by 2032 from its current value of US$ 4.58 billion, with a compound annual growth rate 12.24% in the 2024–2032 period. This expansion is as a result of improvement in the genomic studies, the growing adoption of personalized medicine, and increased incidence of genetic diseases.

The report Europe Next Generation Sequencing Market & Forecast covers by Products (Instruments, Reagents & Consumables, and Services), Application (Diagnostics, Agriculture and Animal Research, Drug Discovery, Personalized Medicine and Genetic Screening), Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-Molecule Read Time Sequencing, Nanopore Sequencing), End-Users(Academic and Clinical Research Centers, Pharmaceutical and Biotechnology Companies, Hospitals and Clinics, and Others), Country and Company Analysis 2024-2032.

Europe Next Generation Sequencing Market Outlooks

Next Generation Sequencing (NGS) is a powerful technique employed for decoding large sample sequences in parallel and in a more timely and cost-effective method compared to other methods. Unlike the conventional methods of sequencing, NGS has the capacity of sequencing millions of DNA fragments within a short span, cost-effective as well as highly accurate. It also too has so many uses for example in the genetic research, genetic medicine or even just in testing diseases. Due to NGS genomics, it is easier to understand the complexities of data, analyze mutations and even perform molecular analysis of diseases.

In European countries NGS is be used broadly in health services and in research. This is commonly employed in cancer research to identify genes, as well as mutations and to design treatment to enhance patient care. Moreover, NGS is being used for diagnosis of RDs where it helps in acquiring faster rates of diagnosis of genetic disorders. Many European health systems and research institutions interest in NGS for personalized medicine, infectious diseases monitoring, and population genomics improving the precise medicine in Europe.

Currently, there is growth in the incidence of cancer across the globe, where 4.4 million new cancer cases in Europe in 2020 with this number anticipated to reach 4.9 million by 2030. The main forms of cancer are lung, breast, colon, prostate and rectum. The performance of NGS in the management of NSCLC and in cancer research as a whole has led with the enhanced elucidation of molecular basis of individual cancers.

Growth Driver of the Europe Next Generation Sequencing Market

Advancements in Genomic Research

Biological and genomic development is another reason for market growth in the European Next Generation Sequencing (NGS). Sequencing processes have also benefitted from improvements in technology since these processes are faster, more accurate and cheaper to accomplish. These are enabling the researchers to work on intricate information involving the genetics and to discover new biomarkers as well as the understanding of the causes of diseases based on genetics. Advancements in this area of the credit has enhanced discoveries in personalized medicine, cancer analysis, and clinical uncommon genetic disorders. Since Europeans research institutions and ‘biotech firm make use of these technologies, the market for NGS services and products expands thus contributing to growth in the market.

Increasing Prevalence of Genetic Disorders

Currently, EC increase in frequency of various genetic disorders, which leads to the growing demand for NGS. With a growing number of patients with genetic disorders – inherited cancers, rare and congenital diseases – more sharply, differentiated diagnostics and treatment plans are required. Next-generation sequencing gives extensive and precise genetic data for the formulation of these disorders’ diagnosis and treatment. This demand for the genetic testing and moving towards personalized medicine is driving the NGS market since health care providers are in search of better diagnostic tools to serve their client better.

Expanding Applications in Personalized Medicine

Expansion across applications in Personalized medicine is identified as a primary growth factor in the European NGS market. As one of the leading products offering personalized medicine where treatment depends on the genetic make-up of the patient, NGS technologies provides the necessary and adequate genetic information. Personalized medicine strategies and targeted therapy applications can be accelerated through NGS since accurate determination of associations between genetic variations and therapeutic outcomes is achievable. It has been observed that with the advent of personalized medicine in the Europe, the healthcare facilities are now investing more in NGS solutions for precision in diagnosis and treatment of the patients and this has fueled the growth of the market.

Barriers in the Europe Next Generation Sequencing Market

Implementation Costs High

The costs of next-generation sequencing (NGS) technology are very high in Europe. These costs encompass the cost of sequencing instruments, reagents, software, and data analysis tools. Moreover, the maintenance and upgrading of these systems require heavy investment. Therefore, the implementation of NGS is not possible for smaller research institutions and healthcare facilities, as the costs are too high for them to incur. Although prices have decreased, affordability is still a concern, especially for publicly funded healthcare systems that need to balance cost-effectiveness with technological advancements.

Data Privacy and Regulatory Challenges

Europe has strict genomic data privacy and security regulations, including GDPR compliance. Handling large amounts of genetic data requires secure storage, processing, and sharing mechanisms, which can be complex and costly. In addition, the differences in regulatory frameworks across various European countries create inconsistencies, making it difficult for companies and research institutions to operate seamlessly across borders. These regulatory hurdles slow the region's adoption and expansion of NGS technologies.

Europe Next Generation Sequencing Instruments Market

The European NGS instruments market is growing due to the increasing demand for high-throughput sequencing in research and clinical applications. Advanced sequencing platforms, such as Illumina and Oxford Nanopore technologies, are widely used for genome analysis, cancer research, and precision medicine. However, the market faces challenges related to the high initial investment costs and the need for skilled personnel to operate these sophisticated instruments. Despite these hindrances, continuing technological developments and government funding in genomics are expected to take the market forward.

Europe Next Generation Sequencing Diagnostics Market

NGS diagnostics is changing the face of disease detection and personalized medicine in Europe. It is used for the precise identification of genetic disorders, infectious diseases, and cancer biomarkers. The European healthcare sector increasingly incorporates NGS in clinical workflows to make early diagnosis and targeted treatments possible. However, reimbursement policies of NGS-based tests significantly differ from countries to countries. Moreover, the pressure of standardized protocols and other regulatory approvals causes a delay in the implementation of new diagnostic tests despite increasing demands for advanced genetic testing. In May 2024, QIAGEN has released an updated version of its clinical decision support platform, QIAGEN Clinical Insight, for NGS molecular profiling of hereditary and somatic diseases. It has the EU Technical Documentation Assessment and Quality Management System certificate under the IVDR 2017/746.

Europe Next Generation Sequencing by Synthesis Market

The NGS by synthesis (NGS-SBS) market in Europe is growing, because of high accuracy and efficiency in sequencing applications. This method, mainly adopted by companies like Illumina, drives the market due to its scalability and cost effectiveness for large-scale sequencing projects. NGS-SBS is commonly used in genomics research, clinical diagnostics, and pharmaceutical development. However, high costs associated with sequencing reagents and an increased need for sophisticated bioinformatics capabilities have made its wider utilization not feasible yet. In the future, R&D investments will continue to drive down the efficiency and cost of this sequencing technology. In October 2024, PacBio launched SPRQ, new sequencing chemistry for its Revio long-read sequencing system. This new chemistry reduces the DNA input requirements by four times, down to 500ng per sample, allowing a wider range of sample types, such as saliva and tumor samples, to be sequenced using HiFi sequencing technology.

Europe Next Generation Sequencing Hospitals and Clinics Market

The adoption of NGS in European hospitals and clinics is increasing due to the growing need for precision medicine and genetic testing. Hospitals leverage NGS for cancer diagnostics, rare disease identification, and personalized treatment plans. However, challenges such as high equipment costs, limited access to trained professionals, and slow reimbursement processes hinder widespread adoption. Despite these challenges, partnerships between healthcare providers, research institutions, and biotechnology companies are pushing the boundaries of the integration of NGS into clinical practice.

France Next Generation Sequencing Market

France is a significant player in the European NGS market. The government initiatives supporting genomic research and precision medicine are driving this market. The country has invested in large-scale projects, such as the France Genomic Medicine Plan 2025, to integrate NGS into clinical applications. The demand for NGS-based diagnostics and drug discovery is on the rise in hospitals and research institutions. However, regulatory complexities and reimbursement challenges will slow down its widespread implementation. Continued investment in genomic infrastructure and innovation will be a boon for France's NGS market in the coming years. NewBiologix SA, the company focused on the technology of innovation in order to address gene therapy manufacturing gaps, announced it launched its NGS and optical mapping platform April 2024 as a new suite of novel technologies combined together for comprehensive genomic analysis services provided to the biopharmaceutical industry.

Germany Next Generation Sequencing Market

Germany’s NGS demand is set to continue growing as more organizations and patients take advantage of genomics and incorporate them into their medical strategies. The improvement in research capabilities and investment on biotechnology of Germany helped in the adaptation of NGS on different study area such as cancer studies, genetic disease, and individualized medicine. Analyzing the German market, the most important advantage of NGS is its possibility of high-throughput analysis, which helps research institutions and hospitals in discovering new biomarkers. Besides, grants and subsidies provided by governments for genomic research also contributes to the growth of the market. With Germany being a key player in the global healthcare industry and with more emphasis being laid on developing innovative healthcare services in Germany and especially on individualized treatment systems, the Germany NGS market is expected to experience considerable growth in the years to come owing to continuing technological advancement as well as its increasing clinical applications. This segment in 2024 is expected to dominate the research and other applications segment in Europe NGS market. The rise in the number of laboratories that are adopting sequencing-based tests, the increasing market for personalized drugs, the use of NGS for research and the rising incidences of genetic diseases. For instance, based on the data from the German Center for Lung Research, July 2024, about 2,500 newborns were diagnosed with cystic fibrosis in 2022.

Europe Next Generation Sequencing Company News

Jul 2024, Permanent reimbursement for next-generation sequencing (NGS) in oncology launched in Belgium.

On August 2023, Almac Diagnostic Services, a member of the Almac Group, invested in expanding its NextNext-Generation Sequencing capabilities for BioPharma partners, following the purchase and installation of the first Illumina NovaSeq™ X Plus instrument in Northern Ireland and the whole island of Ireland.

In June 2024, Illumina Inc. announced that it has completed integrating the latest chemistry, XLEAP-SBS™, into all reagents for its NextSeq™ 1000 and NextSeq 2000 next-generation sequencing (NGS) instruments.

Europe Next Generation Sequencing Market Segments

Product – Market breakup in 3 viewpoints:

1. Instruments
2. Reagents & Consumables
3. Services

Application – Market breakup in 5 viewpoints:

1. Diagnostics
2. Agriculture and Animal Research
3. Drug Discovery
4. Personalized Medicine and Genetic Screening
5. Others

Technology – Market breakup in 5 viewpoints:

1. Sequencing by Synthesis
2. Ion Semiconductor Sequencing
3. Single-Molecule Read Time Sequencing
4. Nanopore Sequencing
5. Others

End-Users – Market breakup in 4 viewpoints:

1. Academic and Clinical Research Centers
2. Pharmaceutical and Biotechnology Companies
3. Hospitals and Clinics
4. Others

Countries – Market of 15 Countries:

1. France
2. Germany
3. Italy
4. Spain
5. United Kingdom
6. Belgium
7. Netherlands
8. Russia
9. Poland
10. Greece
11. Norway
12. Romania
13. Portugal
14. Turkey
15. Rest of Europe

All the Key players have been covered from 5 Viewpoints:

• Overviews
• Key Person
• Recent Developments & Strategies
• Product Portfolio & Product Launch in Last 1 Year
• Revenue

Company Analysis:

1. Illumina
2. Thermo Fisher Scientific
3. Pacific Biosciences of California
4. QIAGEN N.V
5. Roche
6. Bio-Rad Laboratories, Inc.
7. Takara Bio Inc.
8. Hamilton Company
9. Geneious,
10. BioMérieux SA.

Report Details:

Customization Services available

• Analysis of Market Size and Its Segments
• More Company Profiles (Upto 10 without any additional cost):
• Additional Countries (Other than mentioned Countries):
• Region/Country Specific Reports:
• Market Entry Strategy:
• Region-Specific Market Dynamics:
• Regional Market Share Analysis:
• Trade Analysis:
• Production Insights:
• Others Customized Requests:

For more information contact our analysts.

Need More Assistance?

• Talk to our analysts to get more precious information on the current market trends.
• Include more countries and segments and customize the report based on the final requirement.
• Get a competitive advantage in your industry by knowing the report findings and making a positive impact on your revenues and operations.
• Our analysts are always ready to provide more help and pertinent information if you need any additional assistance.